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Abstract
Background and Case Presentation: A patient with nevoid basal cell carcinoma syndrome (Gorlin syndrome) 
presented with two unusual clinical features, i.e. adenocarcinoma of the small bowel and extensive mesenchymal 
proliferation of the lower gastrointestinal tract.
Conclusions: We discuss the possibility that these two features are pathogenetically linked to the formerly 
undescribed patient's PTCH germ line mutation.
Background
Nevoid basal cell carcinoma syndrome (NBCCS), also
known as Gorlin syndrome, is a rare autosomal dominant
d i s o r d e r  c a u s e d  b y  m u t a t i o n s  i n  t h e  P a t c h e d  ( PTCH)
gene on chromosome 9q22. NBCCS patients often have a
coarse facial appearance with macrocephaly, frontal boss-
ing and prognathism. Falx calcification is frequently
found in affected individuals and skeletal anomalies such
as bifid ribs, wedge-shaped or fused vertebra and thumb
deformities are common. Multiple keratocysts of the jaw
can develop between childhood and young adulthood,
and most patients get their first basal cell carcinoma
(BCC) in their early 20s [1]. Although some additional
tumor types such as medulloblastoma, cardiac and ovar-
ian fibromas, and lipomas are known to have an
increased frequency in NBCCS, intestinal tumors are not
known to be part of the clinical phenotype [2]. In the fol-
lowing we describe the clinical, histopathological and
genetic findings in a patient showing a combination of an
unusual phenotype of NBCCS, a rare adenocarcinoma of
the ileum and mesenchymal proliferation of the small
bowel and probably also the stomach.
Case presentation
Medical history
The patient, a Caucasian male, had multiple BCCs surgi-
cally removed from the his face, requiring extensive facial
skin graft repair, at the age of 49. At the age of 52 years he
presented with weight loss and sub-ileus. A CT-scan indi-
cated a stenosing process located proximal to the ileo-
colic valve. Consecutively explorative laparotomy was
performed and showed an obstructing tumor mass at the
terminal ileum that required ileocecal resection extended
to the regional lymph nodes of the mesentery. Due to
unusual histopathological findings esophagogastroduo-
denoscopy and colonoscopy were conducted after the
operation and showed polyploid structures in the stom-
ach (Figure 1) and the neoterminal ileum. Endoscopic
mucosal biopsies were taken from the colon, ileum, duo-
denum and stomach.
At the same time several skin tumors from the patients
shoulder were diagnosed as BCCs, which finally led to the
suspicion of NBCCS. Additionally both hands showed
multiple palmar pits and mild brachydactyly, the left
thumb was enlarged and deformed (Figure 2). Jaw cysts
and intracerebral calcifications were excluded by MRI
scan. Although family history was empty for BCC and
other tumors, the combination of observed alterations of
the hands and multiple BCCs was strongly suggestive of
NBCCS and PTCH gene screening was initiated.
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Pathological findings
Macroscopic examination of the operation specimen
from the terminal ileum showed an ulcerated tumor with
a maximum diameter of 4.5 cm. Microscopic examina-
tion revealed a poorly differentiated adenocarcinoma
composed of glandular and signet ring cell elements (Fig-
ure 3a). The carcinoma infiltrated into the mesenterial
fatty tissue and showed lymphatic vessel invasion. Seven
out of 33 regional lymph nodes presented metastatic
involvement. The TNM classification was: pT3 pN2 (7/
33) cM0 R0 L1 V0 G3 [3]. Immunohistochemical analysis
revealed no evidence for neuroendocrine differentiation
of the carcinoma, i.e. no expression of synaptophysin and
chromogranin A. The signet ring component of the carci-
noma showed an unusual high proliferative index, as
determined by MIB-1 expression, of 90%. The prolifera-
tive index of the glandular component was 50%.
Additionally, the entire non-carcinoma bearing small
bowel showed a coarse nodular appearance of the luminal
surface with intact covering mucosa. After, the nodules
were located in the mucosa and submucosa of the small
intestine with a maximum nodule diameter of 3.5 cm.
Macroscopic examination revealed numerous nodules
(>100) that centred at the muscularis mucosa and
extended into the submucosa and the lamina propria of
the mucosa. The nodules were characterized by unsharp
delineation without forming capsules (Figure 3b). They
were composed of intermingling spindle cells with scant
cytoplasm and bland nuclei (Figure 3c) that seemed to
originate from the muscularis mucosae. The spindle cells
appeared homogeneous and no mitotic activity was visi-
ble. The latter was confirmed by the nearly complete
absence of MIB-1 staining. The proliferative index was
below 1%. Immunohistochemical analysis revealed an
intimate mixture of smooth muscle cells characterized by
strong expression of desmin (Figure 3d) and smooth mus-
cle actin and Schwann cells that expressed S100 (Figure
3e). Antibodies against neurofilament proved the pres-
ence of single neurons, indicating the proliferation of
both, Schwann cells and neuronal cells within the nod-
ules. No expression of CD117 or CD34 was detectable in
the spindle cell tumors arguing against the presence of a
gastrointestinal stromal tumor (GIST). Staining with
Cathepsin D, Synaptophysin and Chromogranin A
revealed only single positive cells, excluding ganglioneu-
romatosis.
The composition of smooth muscle cells, Schwann cells
and neuronal cells and the multifocal occurrence within
the small bowel did not fit into any known histopatholog-
ical classification. These findings are best described as
mesenchymal proliferation with neural and smooth mus-
cle components.
These changes were also found in the endoscopic biop-
sies taken from the terminal ileum and duodenum but
not in those from the colon. Microscopic examination of
the stomach-biopsies showed chronic gastritis due to H.
pylori infection. One biopsy taken in the antrum of the
stomach also showed the unusual spindle cell accumula-
tions described above, but only in small areas close to the
section border and without confirmation of neuronal
Figure 1 Endoscopy of upper GI-tract. Polyploid structure seen in 
the antrum.
Figure 2 Patient's hands. (a) Left hand: broad thumb, mild brachy-
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components. Thus the diagnosis of mesenchymal prolif-
eration with neural and smooth muscle components was
only tentative for the nodules present in the stomach.
Consultation of the Department of Pathology of Basel/
Switzerland (Dr. E. Bruder) confirmed our findings.
Mutation screening
Sequencing of all 23 coding exons and adjacent intronic
sequences of the PTCH gene led to the detection of a
heterozygous stop codon mutation (c.1136_1137AC>GA;
p.Y379X) in exon 8. The adjacent nucleotides adenine
and cytosine in position 1136 and 1137 of the PTCH gene
were mutated into guanine and adenine, respectively,
changing a codon for tyrosine into a stop codon. This
mutation has not been described before. It can be
expected to completely abolish PTCH function, with seri-
ous consequences for the sonic hedgehog signalling path-
way. The mutation confirmed the clinical diagnosis of
NBCCS in our patient (Figure 4).
Discussion
The NBCCS patient described here displays two unusual
clinical features, small bowel adenocarcinoma and exten-
sive mesenchymal proliferation with neural and smooth
muscle components of the small bowel. Endoscopic
examination and histopathological studies of biopsies
provided an educated guess that the stomach was
involved too. Although the small bowel represents 75% of
the length and 90% of the surface of the GI-tract, tumors
of the small bowel account only for 2% of all GI-malig-
nancies. The rarity of the respective conditions strongly
argues against an independent occurrence of both, small
bowel carcinoma and NBCCS in our patient. Given the
Figure 3 Small intestine histopathology. (a): Poorly differentiated adenocarcinoma composed of malignant glands (bottom, right) and diffusely 
distributed cancer cells (top, left). (b): Low power magnification of small intestine mucosa showing two separate spindle cell nodules in the deep mu-
cosa. (c): Higher magnification of a spindle cell nodule shows bland cytological features of the tumor cells. (d): Immunostaining for desmin highlights 
the lamina muscularis mucosae as well as approximately half of the tumor cells. (e): Immunostaining of the same area for s100 decorates nerve fibres 
in the submucosa as well as the rest of the tumor cells.
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odds it is much more likely that a causative relation
between the carcinoma and the PTCH germ line muta-
tion exists. The same argument holds true for the mesen-
chymal proliferation present in the patient's GI tract. It is
more likely that this previously not described finding is
causally linked to the mutation in the tumor suppressor
gene  PTCH than that it represents the outcome of an
entirely independent pathogenetic chain of events.
The PTCH protein acts in a negative feedback pathway
as a receptor for different hedgehog proteins [4]. As a key
regulator of embryonic development hedgehog signalling
is involved in cell growth and differentiation in a wide
variety of tissues and organs. The PTCH germ line muta-
tions in NBCCS patients are either inherited from an
affected parent or due to de novo events in a parental
germ cell. The truncating germ line mutation found in
our patient is likely to abolish the function of one copy of
PTCH. However, it can not be completely excluded that a
severely truncated form of the protein is produced that
might interfere with the normal PTCH gene product,
causing some kind of clinical phenotype. Tumorigenesis
starts if inactivation of the second, normal PTCH allele by
either loss-of-heterozygosity or point mutation occurs by
chance in a single cell (two-hit mutagenesis). The result-
ing reactivation of the hedgehog/PTCH pathway not only
causes basal cell carcinoma, but also contributes to the
formation of tumors such as medulloblastoma and rhab-
domyosarcoma [5]. Furthermore, several recent studies
found evidence for an involvement of hedgehog signalling
and PTCH in tumorigenesis of the GI- tract. Animal
studies have shown that hedgehog signalling is crucial for
the normal development of the gut [6]. Reactivation of
this pathway is therefore likely to start uncontrolled cell
growth, and it has already been demonstrated that hedge-
hog signalling is widely active in sporadic gut-derived
tumors [7]., Ligand-dependent activation of the hedge-
hog/PTCH pathway by various external stimuli such as
injury of the GI epithelium by acid, alcohol or Helico-
bacter pylori infection has been identified as the main
pathomechanism underlying this observation [8]. The
coexistence of a PTCH germ line mutation and a rare
small bowel adenocarcinoma in our patient might indi-
cate that a two-hit mutational inactivation of PTCH is a
second though probably rare pathomechanism in GI
malignancies.
A highly unusual finding in our patient were the spin-
dle-cell masses in the small bowel that displayed a high
degree of cellular inhomogenity. Leiomyomatosis in the
GI-tract has been reported occasionally in syndromes
such as neurofibromatosis type 1 and tuberous sclerosis,
but without the neural cell component found in our
patient [9-11]. It is therefore tempting to speculate that
reactivation of the PTCH/hedgehog pathway might have
induced the growth of spindle cells in the GI-tract of our
patient. The variability of cell types present can be
explained by the important role of sonic hedgehog signal-
ling in the activation and differentiation of progenitor
cells. Hedgehog signalling has shown to promote the
development of neural crest cells that are capable of mul-
tilineage differentiation. These cells give rise not only to
neurons and glial cells but also to different types of mes-
enchymal cells including smooth muscle and connective
tissue cells [11]. This role in the development of multipo-
tent progenitor cells fits with the coexistence of neural
and smooth muscle cells seen in the immunohistochemi-
cal analysis of the spindle-cell nodules.
Conclusion
Several questions remain: does our patient just represent
an exotic case or is mesenchymal proliferation with neu-
ral and smooth muscle components of the small bowel a
so far unknown clinical feature of NBCCS? Are both the
mesenchymal proliferation and the small bowel carci-
noma pathogenetically linked to the PTCH stop codon
mutation? The fact that mesenchymal proliferation of the
small bowel has not been previously reported in NBCCS
does not necessarily exclude it from the list of possible
complications. As long as it remains asymptomatic such
feature is likely to remain unrecognized because the small
bowel is not included in routine diagnosis of the GI-tract.
If the adenocarcinoma in our patient is indeed pathoge-
netically connected with the mesenchymal proliferation,
the malignant potential of the later is probably too low to
raise a red flag in a syndrome this rare. More patients
with this rare familial tumor syndrome need to be clini-
cally evaluated to see if the mesenchymal proliferation in
the small bowel should be added to the phenotypic spec-
trum of NBCCS.
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Figure 4 Results of sequencing. Heterozygous stop codon mutation 
(c.1136_1137AC>GA; p.Y379X) found in exon 8 is shown. Mutated nu-
cleic acids are indicated by arrows.Prodinger et al. BMC Cancer 2010, 10:360
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